(Q35671182)

English

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).

scientific article published on 23 June 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor). (English)

1 reference

Europe PubMed Central

9 August 2017

relapsing-remitting multiple sclerosis

1 reference

based on heuristic

inferred from title

Catharina C Gross

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26099927%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Tilman Schneider-Hohendorf

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26099927%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Nicholas Schwab

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26099927%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26099927%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

10

object named as

Sven G Meuth

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26099927%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Luisa Klotz

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26099927%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Berit Grützke

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26099927%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Michael Deppe

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26099927%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Lucienne Kirstein

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26099927%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Anita Posevitz-Fejfar

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26099927%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Maria Eveslage

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26099927%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

23 June 2015

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26099927%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26099927%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

96

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26099927%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

copyright license

Creative Commons Attribution 4.0 International

23 June 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1186/s12883-015-0354-9

0 references

Fingolimod treatment promotes regulatory phenotype and function of B cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

12 July 2018

Immunology of progressive multifocal leukoencephalopathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

12 July 2018

Effects of blood transportation on human peripheral mononuclear cell yield, phenotype and function: implications for immune cell biobanking.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

12 July 2018

Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

12 July 2018

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

12 July 2018

Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

12 July 2018

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

12 July 2018

VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

12 July 2018

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

12 July 2018

Fingolimod after natalizumab and the risk of short-term relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

12 July 2018

T-cell response against varicella-zoster virus in fingolimod-treated MS patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

12 July 2018

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

12 July 2018

Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

12 July 2018

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

12 July 2018

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

12 July 2018

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

12 July 2018

Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

12 July 2018

S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

12 July 2018

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

12 July 2018

Rapid whole blood analysis of virus-specific CD4 and CD8 T cell responses in persistent HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

12 July 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

12 July 2018

Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

25 September 2018

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

25 September 2018

L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

25 September 2018

Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

25 September 2018

Immunological and clinical consequences of treating a patient with natalizumab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

25 September 2018

Anti-JC virus antibodies: implications for PML risk stratification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

25 September 2018

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

25 September 2018

The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

25 September 2018

A controlled trial of natalizumab for relapsing multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

25 September 2018

Natalizumab effects on immune cell responses in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477482

25 September 2018

Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped

1 reference

https://pubmed.ncbi.nlm.nih.gov/26099927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?

1 reference

https://pubmed.ncbi.nlm.nih.gov/26099927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD49d expression as a promising biomarker to monitor natalizumab efficacy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26099927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A safety and pharmacokinetic study of intravenous natalizumab in patients with MS

1 reference

https://pubmed.ncbi.nlm.nih.gov/26099927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26099927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunology of multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26099927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE

1 reference

https://pubmed.ncbi.nlm.nih.gov/26099927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26099927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S12883-015-0354-9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26099927%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26099927%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26099927%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35671182&oldid=1900266218"